Research Topics
| Dominique FargeSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Autologous stem cell transplantation for systemic sclerosisDominique Farge
Service de Medecine Interne, Hopital Saint Louis, Paris, France
Autoimmunity 41:616-24. 2008..This review reports the current data concerning the effects of HSCT on survival, skin, and major organ function in patients with severe dcSSc...- Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II studyDominique Farge
Service de Medecine Interne, site transfusionnel de Saint Louis, France
Br J Haematol 119:726-39. 2002..Non-myeloablative conditioning, followed by a T cell-depleted autologous PBSC or bone marrow transplantation, appears feasible with low toxicity in severe SSc with short-term clinical benefits... - [Bone marrow transplantation in the treatment of autoimmune disease]D Farge
, , INSERM U697, 1 avenue Claude-Vellefaux, 75010 Paris, France
Rev Med Interne 28:S285-7. 2007 - Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patientsDominique Farge
Service de médecine interne et pathologie vasculaire, Hôpital Saint Louis and INSERM U976, Assistance Publique Hopitaux de Paris, Paris, France
Thromb Res 125:S108-16. 2010.... - Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune DiseasesDominique Farge
Service de Médecine Interne et Unité INSERM U 976, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris 7 Université Denis Diderot, 1 avenue Claude Vellefaux, 75 010 Paris France
Haematologica 95:284-92. 2010..We evaluated the long-term outcomes of these transplants and aimed to identify potential prognostic factors... - In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetilNina Roos
Institut National de la Santé et de la Recherche Médicale U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, 75010 Paris, France
J Pharmacol Exp Ther 321:583-9. 2007..g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD... - Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen latticesCharlotte Tacheau
INSERM U697, 1 avenue Claude Vellefaux, 75010 Paris, France
Eur J Pharmacol 573:65-9. 2007..These data thus indicate that the inhibitory effect of halofuginone on fibroblast contractile activity, a key function for wound healing implicated in the development of tissue fibrosis, is an ERK-mediated mechanism... - Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosisDominique Farge
Hopital Saint Louis, Paris, France
Arthritis Rheum 52:1555-63. 2005..To analyze hematopoietic and immune reconstitution after autologous hematopoietic stem cell transplantation (HSCT) in 7 patients with systemic sclerosis (SSc)... - Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoringDavid Launay
Service de Medecine Interne, Hopital Claude Huriez, Universite Lille 2, Lille, France
J Rheumatol 36:1460-3. 2009..Using high resolution computed tomography (HRCT), to assess the lung involvement outcome after autologous hematopoietic stem cell transplant (AHSCT) in patients with scleroderma (systemic sclerosis, SSc)... - Impact of pain in health related quality of life of patients with systemic sclerosisC Georges
Internal Medicine Department, Saint Louis Hospital, Service de Medecine Interne, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
Rheumatology (Oxford) 45:1298-302. 2006..The aim of the study is as to evaluate the quality of life (QoL) in patients with either diffuse or limited SSc, and to examine the impact of pain on the QoL scores... - Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosisFranck Verrecchia
INSERM U697, Hopital Saint Louis, Pavillon Bazin, 1 avenue Claude Vellefaux, Paris, France
Autoimmun Rev 5:563-9. 2006..Potential implications for the development of therapeutic approaches against tissue fibrosis during SSc are discussed... - Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyGuy Meyer
Department of Respiratory and Critical Care Medicine, Hopital Europeen Georges Pompidou, Paris V University, France
Arch Intern Med 162:1729-35. 2002..The use of low-molecular-weight heparin sodium for secondary prevention of venous thromboembolism in cancer patients may reduce the complication rate... - [Cardiopulmonary function before and after cyclophosphamide treatment in severe systemic sclerosis: comparison of monthly intravenous bolus and autologous haematopoietic stem cell transplantation]C Toledano
Service de Medecine Interne, Hopital Saint Louis, Paris, France
Rev Med Interne 26:444-52. 2005..Cyclophosphamide potential cardiotoxicity in this setting has been questioned... - Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ)C Georges
AP HP, Internal Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
Clin Rheumatol 24:3-10. 2005..In addition, we suggest the use of a new outcome measure, the SSc HAQ score, to assess this systemic disease more accurately... - [Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]C Georges
Service de Medecine Interne, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris 10, France
Rev Med Interne 25:16-21. 2004.... - Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosisJulie Baraut
INSERM U976, Pavillon Bazin, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
Autoimmun Rev 10:65-73. 2010..Restoration of the Th1/Th2/Th17/Treg balance is one of the hallmarks of treatment effectiveness and development of cytokine modulators could be considered for new therapeutic approaches in SSc patients... - [Therapeutic intensification and autologous stem cell transplantation in autoimmune diseases]Z Marjanovic
, Service de Greffe de Moelle, , 1, avenue Claude Vellefaux, 75010 Paris, France
Presse Med 34:311-8. 2005..A STUDY PROJECT IS PLANNED FOR MULTIPLE SCLEROSIS (Astims, Autologous Stem cell Transplantation International Multiple Sclerosis)... - [Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?]J Larghero
Unité de Thérapie Cellulaire, Hopital Saint Louis, AP HP, Paris, France
Rev Med Interne 30:287-99. 2009..Phase I-II studies are in progress in various countries to investigate the potential benefit from MSC due to their immunosuppressive properties, as an adjunctive therapy for severe refractory autoimmune disease... - Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosisJ Larghero
Cell Therapy Unit, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
Ann Rheum Dis 67:443-9. 2008..Mesenchymal stem cells (MSCs) have a potential immunomodulatory role in autoimmune disease; however, the qualitative properties and haematopoietic support capacity of MSCs derived from patients with autoimmune disease is unclear... - Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR RegistryD Farge
St Louis Hospital, Paris, France
Ann Rheum Dis 63:974-81. 2004..This EBMT/EULAR report describes the longer outcome of patients originally described in addition to newly recruited cases... - Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosisFranck Verrecchia
INSERM U697, , 1 avenue Claude Vellefaux, 75010 Paris, France
Expert Rev Clin Immunol 5:35-43. 2009..Since 1996, this drug has been used at higher doses for autologous hematopoietic stem cell transplantations, permitting rapid and durable clinical and histological regression of skin fibrosis... - 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working groupDominique Farge
Service de médecine interne et pathologie vasculaire, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and INSERM U976, Paris VII University, France
Crit Rev Oncol Hematol 73:31-46. 2010.... - Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?Nicolas Poulalhon
INSERM U697, , 75010 Paris, France
J Biol Chem 281:33045-52. 2006..It thus appears that rapamycin may exert direct antifibrotic activities independent from its immunosuppressive action... - [Vulnerable populations: risk factors and evaluation. Measures of protection]Marjan Daneshpouy
, , 75010 Paris
Rev Prat 55:887-92. 2005 - [Hospital LOS, medical complexity and deprivation indicators]J Holstein
Département d information médicale, Assistance Publique Hopitaux de Paris, Paris Cedex 04, France
Rev Epidemiol Sante Publique 57:205-11. 2009..Hence, we aimed at extracting routinely available variables measuring deprivation from the Hospital Information System and at assessing their association with severity of illness and hospital LOS... - Azathioprine or methotrexate maintenance for ANCA-associated vasculitisChristian Pagnoux
Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
N Engl J Med 359:2790-803. 2008..However, azathioprine and methotrexate have not been compared with regard to safety and efficacy... - Skin involvement in scleroderma--where histological and clinical scores meetF Verrecchia
INSERM U697, Paris, France
Rheumatology (Oxford) 46:833-41. 2007.... - Prognostic value of quantitative Kaposi sarcoma--associated herpesvirus load in posttransplantation Kaposi sarcomaClaire Pellet
Laboratory of Pharmacology, , Paris, France
J Infect Dis 186:110-3. 2002..01). Thus, quantification of KSHV load in peripheral blood mononuclear cells could represent a useful tool for monitoring transplant recipients with KS... - [Follow-up with the assistance of TB-info software of 208 tuberculosis patients who were treated in 2004]A Bourgarit
Hopital Saint Louis, Paris, France
Rev Med Interne 30:841-6. 2009..The impact of the TB-info software was assessed on the care of patients treated with antituberculosis regimen (ATT)... - Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetesL Vija
INSERM U697, Paris, France
Diabetes Metab 35:85-93. 2009..In this review, we provide a brief characterization of MSC immunomodulatory effects, and present the current experimental evidence for the potential therapeutic efficacy of MSC transplantation in diabetes... - European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature researchJ Avouac
Rheumatology A Department, RDU, Paris, France
Ann Rheum Dis 68:629-34. 2009..In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail... - Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group DatabaseChristian Pagnoux
Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
Arthritis Rheum 62:616-26. 2010..This study was undertaken to describe the main characteristics of and long-term outcomes in patients with well-characterized PAN diagnoses... - Autologous stem cell transplantation for systemic lupus erythematosusDavid Jayne
Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
Lupus 13:168-76. 2004..The safety of this procedure is likely to be improved by patient selection and choice of conditioning regimen. The return of disease activity in one-third of patients might be reduced by long-term immunosuppressive therapy post-ASCT...